EU countries can buy 300m more doses of BioNTech-Pfizer Covid-19 vaccine

The Commission has secured altogether up to 2.3 billion jabs from the most promising producers

Photo: EU Ursula von der Leyen.

The Commission proposed to the EU countries to purchase an additional 300 million doses of the Covid-19 vaccine produced by BioNTech and Pfizer. This was announced by  EC President Ursula von der Leyen at a news conference she gave on Friday morning.

We make sure Europeans have sufficient doses of safe and effective Covid-19 vaccines and we now enable EU countries to buy more doses of the first vaccine approved in EU, von der Leyen told the press.

This would enable the EU to purchase up to 600 million doses of this vaccine, which is already being used across the EU.

The additional doses will be delivered starting in the second quarter of 2021.

As von der Leyen underlined, the EU has acquired a broad portfolio of different vaccines and has secured up to 2.3 billion doses from the most promising vaccine candidates for Europe and its neighbourhood. 

In addition to the BioNTech-Pfizer vaccine, a second vaccine, produced by Moderna, was authorised on 6 January 2021. Other vaccines are expected to be approved soon. 

This vaccine portfolio would enable the EU not only to cover the needs of its whole population, but also to supply vaccines to neighbouring countries.

The only framework we are negotiating vaccines is as 27 and we do this together, the EC President reaffirmed adding that “no Member State on this legal binding basis is allowed to negotiate in parallel or to have a contract in parallel”.

Similar articles